Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Single-Agent Ibrutinib As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice in Spain

Pau Abrisqueta Costa, Javier Loscertales, MD, Maria Jose Terol, Angel Ramirez Payer, Macarena Ortiz Pareja, Inmaculada Perez, Carolina Cuellar, Margarita Fernandez De La Mata, Alicia Rodriguez, MD, Ana Lario, Julio Delgado, MD, Ana Cristina Godoy, PhD, Jose M Arguiñano, Maria José Berruezo, Ana C Oliveira, MD PhD, Jose Angel Hernandez-Rivas, MD PhD, María-Dolores García-Malo, MD, Angeles Medina, MD, Paloma García Martín, Santiago Osorio-Prendes, MD, Patricia Baltasar, Miguel Fernandez, MD, Fernando Marco, María-Jesús Vidal, Alicia Susana Smucler Simonovich, Montserrat Lopez Rubio, PhD, Isidro Jarque, Alexia Suárez Cabrera, Ruben Fernandez, MD, Aima Lancharro Anchel, Eduardo Rios Herranz, Carmen Losada, Ernesto Pérez Persona, Ricardo Francisco Garcia, Dr., Rafael Ramos, Lucrecia Yáñez, MD PhD, Jose Luis Bello, MD, Cristina Loriente, Miguel Villanueva

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-136036

Published: 2020

Journal Articles

Rapid Infusion with CT-P10 in Patients with Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukaemia: Interim Six Month Follow-up from a European Non-Interventional Post-Authorisation Safety Study

Mark Bishton, Pier Luigi Zinzani, MD PhD, Scott Marshall, Veronica Conteh, Alicia Rodríguez Fernández, SooKyoung Kim, Young Nam Lee

Blood (2019) 134 (Supplement_1): 4135.

https://doi.org/10.1182/blood-2019-121957

Published: 2019

Journal Articles

Phase II Trial to Evaluate the Efficacy and Safety of the Combination of Obinutuzumab and Bendamustine Treatment in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Blood (2017) 130 (Supplement 1): 4321.

https://doi.org/10.1182/blood.V130.Suppl_1.4321.4321

Published: 2017

Journal Articles

Clinical, Genomic Profile and Recurrent Somatic Mutations in 205 Chronic Lymphocytic Leukemia Treatment-Naive Patients

Blood (2017) 130 (Supplement 1): 1715.

https://doi.org/10.1182/blood.V130.Suppl_1.1715.1715

Published: 2017

Journal Articles

The Molecular Response at 3 Months, Measured Using a Genxpert Platform, Predicts Further Outcomes in Chronic Myeloid Patients, but the Cutoff Differs from the 10% Cutoff Commonly Used with the EUTOS Method

Valentín García Gutiérrez, María Teresa Gómez-Casares, Jose Manuel Puerta, Juan Manuel Alonso, Santiago Osorio, Juan Carlos Hernández-Boluda, Rosa Collado, Maria Jose Ramirez, MD, Fatima Ibañez, MD, Maria Luisa Martin, Juan Diego Rodriguez, Carolina Martinez-Laperche, Montse Gomez, Viviana Fiallo, Redondo Sara, Alicia Rodriguez, Concepcion Ruiz, Juan Luis Steegmann, MD, Antonio Jiménez-Velasco, MD

Blood (2016) 128 (22): 1906.

https://doi.org/10.1182/blood.V128.22.1906.1906

Published: 2016

Journal Articles

Molecular Response at 3 Months Measured with Genexpert BCR-ABL (IS) Platform Predicts Further Outcome in Chronic Myeloid Patients but the Cutoff Differs from the 10% Commonly Used with BCR-ABL (IS) EUTOS Method

Valentín García-Gutierrez, Maria Teresa Gómez Casares, Jimenez Velasco Antonio, Alonso Juan Manuel, Santiago Osorio, Juan Carlos Hernández-Boluda, Jose Manuel Puerta, Rosa Collado, Maria Jose Ramirez, Fatima IbaÃ±ez, María Luisa Martín Mateos, Juan Diego Rodriguez Gambarte, Carolina Martinez Laperche, Sara Redondo, Montse Gomez, DV Suarez Fiallo, Alicia Rodriguez Fernandez, Concepcion Ruiz, Juan Luis Steegmann, MD

Blood (2015) 126 (23): 2776.

https://doi.org/10.1182/blood.V126.23.2776.2776

Published: 2015

Journal Articles

Development of a High-Throughput Screening Assay with Nurse-like Cell-Based Microenviroment in Chronic Lymphoid Leukemia Cells.

Blood (2014) 124 (21): 3639.

https://doi.org/10.1182/blood.V124.21.3639.3639

Published: 2014

Journal Articles

Prospective, Observational Study to Assess the Safety of Rituximab(R) in Combination with Chemotherapy in Patients with Previously-Untreated or Relapsed or Refractory B Cell-Lineage Chronic Lymphocytic Leukaemia (B-CLL): Final Results

Pilar Giraldo, MD PhD, Andres Lopez, MD PhD, Eduardo Rios, MD, Felix Carbonell, MD PhD, Javier Lopez, Angel Ramírez, MD, Alicia Rodriguez, MD, Marta Gomez, MD, Ricardo Garcia, MD, Patricia Baltasar, MD, Maria Duran, MD, Raul Perez, MD, Maria Garcia, MD, José Antonio Márquez, Javier De la Serna, MD PhD

Blood (2014) 124 (21): 5666.

https://doi.org/10.1182/blood.V124.21.5666.5666

Published: 2014

Journal Articles

Chromosome 8 Abnormalities (8p Losses and 8q Gains) in Patients with Chronic Lymphocytic Leukemia (CLL) and Del(17p)

Blood (2014) 124 (21): 5638.

https://doi.org/10.1182/blood.V124.21.5638.5638

Published: 2014

NARROW

Single-Agent Ibrutinib As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice in Spain

Rapid Infusion with CT-P10 in Patients with Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukaemia: Interim Six Month Follow-up from a European Non-Interventional Post-Authorisation Safety Study

Phase II Trial to Evaluate the Efficacy and Safety of the Combination of Obinutuzumab and Bendamustine Treatment in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Clinical, Genomic Profile and Recurrent Somatic Mutations in 205 Chronic Lymphocytic Leukemia Treatment-Naive Patients

The Molecular Response at 3 Months, Measured Using a Genxpert Platform, Predicts Further Outcomes in Chronic Myeloid Patients, but the Cutoff Differs from the 10% Cutoff Commonly Used with the EUTOS Method

Molecular Response at 3 Months Measured with Genexpert BCR-ABL (IS) Platform Predicts Further Outcome in Chronic Myeloid Patients but the Cutoff Differs from the 10% Commonly Used with BCR-ABL (IS) EUTOS Method

Development of a High-Throughput Screening Assay with Nurse-like Cell-Based Microenviroment in Chronic Lymphoid Leukemia Cells.

Prospective, Observational Study to Assess the Safety of Rituximab(R) in Combination with Chemotherapy in Patients with Previously-Untreated or Relapsed or Refractory B Cell-Lineage Chronic Lymphocytic Leukaemia (B-CLL): Final Results

Chromosome 8 Abnormalities (8p Losses and 8q Gains) in Patients with Chronic Lymphocytic Leukemia (CLL) and Del(17p)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only